Adjunctive brivaracetam for refractory partial-onset seizures: a randomized, controlled trial
J A French,C Costantini,A Brodsky,P von Rosenstiel,N01193 Study Group,Fernando Cendes,Arthur Cukiert,Maria Luiza Manreza,Americo Sakamoto,Marielza Veiga,Roger Walz,Elza Yacubian,Atul Agarwal,Joy Desai,SitaJaylakshmi Sattuluri,Sangeeta Ravat,Parthasarathy Satishchandra,Devanathan Vasudevan,Leopoldo Rivera Castano,Manuel Ojeda Chavarría,Jose Luis Oropeza de Alba,Lourdes Leon Flores,Albino Contreras Milian,Sarug Reyes Morales,Jeronimo Rodriguez Rodriguez,Bassel Abou-Khalil,John Absher,Perminder Bhatia,Victor Biton,Edwin Cruz,Michael Ehrlich,Gerald Ferencz,Stephen Flitman,Jacqueline French,Justin Graff,John Grubbs,Cynthia Harden,Pavel Klein,Kenneth Laxer,Robert Leroy,Joel Oster,Bassel Shneker,Michael Sperling,Athar Syed,Timothy Thoits,Colin Van Orman
DOI: https://doi.org/10.1212/WNL.0b013e3181ec7f7f
IF: 9.9
2010-08-10
Neurology
Abstract:Objective: To explore efficacy and safety/tolerability of adjunctive brivaracetam (BRV), a novel, high-affinity synaptic vesicle protein 2A ligand, which also inhibits neuronal voltage-dependent sodium channels, in patients with refractory partial-onset seizures (POS). Methods: This was an exploratory, phase IIb, double-blind, randomized, parallel-group, placebo-controlled, dose-ranging study in patients 16-65 years with epilepsy experiencing > or =4 POS during 4-week baseline despite 1-2 concomitant antiepileptic drugs. Patients were randomized (1:1:1:1) to placebo, BRV 5 mg/day (BRV5), BRV 20 mg/day (BRV20), or BRV 50 mg/day (BRV50), administered BID without uptitration during a 7-week treatment period. Primary efficacy endpoint was POS frequency/week during the treatment period relative to placebo. Results: A total of 208 patients constituted the intention-to-treat population; 197 completed the study. Estimated percentage reductions over placebo in POS frequency/week were 9.8% (BRV5; p = 0.240), 14.9% (BRV20; p = 0.062), and 22.1% (BRV50; p = 0.004). Median percent reductions from baseline in POS frequency/week were 21.7% (placebo), 29.9% (BRV5; p = 0.086), 42.6% (BRV20; p = 0.014), and 53.1% (BRV50; p < 0.001); > or =50% responder rates were 16.7% (placebo), 32.0% (BRV5; p = 0.047), 44.2% (BRV20; p = 0.002), and 55.8% (BRV50; p < 0.001); seizure freedom rates (POS) during the 7-week treatment period were 1.9% (placebo), 8.0% (BRV5; p = 0.193), 7.7% (BRV20; p = 0.193), and 7.7% (BRV50; p = 0.201). BRV was well-tolerated. Most adverse events were mild to moderate and occurred with similar incidence in placebo and BRV groups, and discontinuations due to treatment-emergent adverse events were infrequent (placebo 3.7%; BRV 2.6%). Conclusions: This interventional study provides preliminary Class I evidence that adjunctive BRV was efficacious and well-tolerated in patients aged 16-65 years with POS.